Advanced analytics Bioneer offers LC-MS expansion and advanced analytical capabilities, enabling deeper protein insights for drug discovery and development. This creates a sales opportunity to position the firm as a one-stop partner for early-stage characterisation and mechanism studies for biotech and pharma clients seeking robust data to de-risk candidates.

Integrated R&D partner As a trusted strategic CRO with nearly four decades in operation and two Copenhagen-area sites, Bioneer presents a compelling value proposition for mid- to late-stage biotech companies seeking extended R&D teams, integrated services, and continuity across discovery and preclinical phases.

Neuronal science niche Recent launches such as the astrocyte-neuron co-culture system open doors to CNS and neurodegeneration programs. This suggests opportunities to target customers pursuing neuronal maturation and electrophysiological assessments, where Bioneer’s unique platform can differentiate from generic CROs.

Collaborative resilience Partnerships like the Danish Technological Institute resilience consortium indicate strength in collaborative initiatives. Sales conversations can emphasize Bioneer’s ability to join multi-party programs, contribute specialized capabilities, and accelerate time-to-insight in complex research initiatives.

Emerging biological services The historical use of CRISPR-Cas9 tooling and DNA enrichment workflows, alongside ongoing CRO services, points to a broad capability set adaptable to customizable early drug candidate development, enabling outreach to biotech startups and SME pharmaceutical companies seeking agile, innovative R&D support.